Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aldehyde dehydrogenase 1 (ALDH1) has been regarded as a breast cancer stem cell marker. Several studies have reported that ALDH1 expression is associated with poor prognosis in breast cancer. We aimed, therefore, to determine the prognostic value of ALDH1 expression and its association with several biomarkers in breast cancer tissue using immunohistochemistry. Furthermore, we investigated the characteristics of and differences between cellular and stromal expression of ALDH1. We performed tissue microarray (TMA) analysis of 425 breast cancer tissue samples collected during surgery. Immunohistochemical staining was then performed to measure the expression of ALDH1 and other breast cancer biomarkers. Statistical analysis of the relationship between ALDH1 expression and clinicopathologic characteristics was performed for 390 TMA samples. We found that ALDH1 was expressed in 71 cases (18.2%) in the tumor cells and/or stroma. Of these cases, 38 (9.7%) showed ALDH1 expression in tumor cells and 38 (9.7%) showed ALDH1 expression in the stroma. ALDH1 expression was significantly associated with markers of a poor prognosis, such as young age, estrogen receptor negativity, progesterone receptor negativity, a high histological grade, and a high Ki-67 index. However, ALDH1 expression was not associated with p53, transforming growth factor-beta, Gli-1, YKL-40, or sonic hedgehog expression status. With regard to the expression site, the clinical characteristics did not differ between cases of cellular expression and those of stromal expression. However, ALDH1 expression in tumor cells was correlated with hormone receptor status, histological grade, molecular subtype, epidermal growth factor receptor expression status, and cytokeratin 5/6 expression status while stromal expression of ALDH1 was only correlated with hormone receptor status. Overall, these findings suggest that ALDH1 expression in tumor tissue is associated with a biologically aggressive phenotype.

Original languageEnglish
Pages (from-to)352-362
Number of pages11
JournalNeoplasma
Volume61
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Breast Neoplasms
aldehyde dehydrogenase 1
Neoplasms
Keratin-6
Tissue Array Analysis
Keratin-5
Hormones
Neoplastic Stem Cells
Progesterone Receptors
Tumor Biomarkers
Epidermal Growth Factor Receptor
Transforming Growth Factor beta
Estrogen Receptors
Biomarkers
Immunohistochemistry
Staining and Labeling
Phenotype

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{93786dd62cf44176bd3caab54abb2f52,
title = "Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer",
abstract = "Aldehyde dehydrogenase 1 (ALDH1) has been regarded as a breast cancer stem cell marker. Several studies have reported that ALDH1 expression is associated with poor prognosis in breast cancer. We aimed, therefore, to determine the prognostic value of ALDH1 expression and its association with several biomarkers in breast cancer tissue using immunohistochemistry. Furthermore, we investigated the characteristics of and differences between cellular and stromal expression of ALDH1. We performed tissue microarray (TMA) analysis of 425 breast cancer tissue samples collected during surgery. Immunohistochemical staining was then performed to measure the expression of ALDH1 and other breast cancer biomarkers. Statistical analysis of the relationship between ALDH1 expression and clinicopathologic characteristics was performed for 390 TMA samples. We found that ALDH1 was expressed in 71 cases (18.2{\%}) in the tumor cells and/or stroma. Of these cases, 38 (9.7{\%}) showed ALDH1 expression in tumor cells and 38 (9.7{\%}) showed ALDH1 expression in the stroma. ALDH1 expression was significantly associated with markers of a poor prognosis, such as young age, estrogen receptor negativity, progesterone receptor negativity, a high histological grade, and a high Ki-67 index. However, ALDH1 expression was not associated with p53, transforming growth factor-beta, Gli-1, YKL-40, or sonic hedgehog expression status. With regard to the expression site, the clinical characteristics did not differ between cases of cellular expression and those of stromal expression. However, ALDH1 expression in tumor cells was correlated with hormone receptor status, histological grade, molecular subtype, epidermal growth factor receptor expression status, and cytokeratin 5/6 expression status while stromal expression of ALDH1 was only correlated with hormone receptor status. Overall, these findings suggest that ALDH1 expression in tumor tissue is associated with a biologically aggressive phenotype.",
keywords = "ALDH1, Biologically aggressive, Breast cancer",
author = "Kang, {Eun Joo} and H. Jung and Woo, {Ok Hee} and Park, {Kyong Hwa} and Woo, {Sang- Uk} and Dae-Sik Yang and Aeree Kim and Lee, {Jae Bok} and Kim, {Yeul Hong} and Kim, {Jun Suk} and Seo, {Jae Hong}",
year = "2014",
month = "1",
day = "1",
doi = "10.4149/neo_2014_045",
language = "English",
volume = "61",
pages = "352--362",
journal = "Neoplasma",
issn = "0028-2685",
publisher = "Vydavatel'stvo Slovenkej Akademie Vied/Veda Publishing House of the Slovak Academy of Sciences",
number = "3",

}

TY - JOUR

T1 - Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer

AU - Kang, Eun Joo

AU - Jung, H.

AU - Woo, Ok Hee

AU - Park, Kyong Hwa

AU - Woo, Sang- Uk

AU - Yang, Dae-Sik

AU - Kim, Aeree

AU - Lee, Jae Bok

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

AU - Seo, Jae Hong

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aldehyde dehydrogenase 1 (ALDH1) has been regarded as a breast cancer stem cell marker. Several studies have reported that ALDH1 expression is associated with poor prognosis in breast cancer. We aimed, therefore, to determine the prognostic value of ALDH1 expression and its association with several biomarkers in breast cancer tissue using immunohistochemistry. Furthermore, we investigated the characteristics of and differences between cellular and stromal expression of ALDH1. We performed tissue microarray (TMA) analysis of 425 breast cancer tissue samples collected during surgery. Immunohistochemical staining was then performed to measure the expression of ALDH1 and other breast cancer biomarkers. Statistical analysis of the relationship between ALDH1 expression and clinicopathologic characteristics was performed for 390 TMA samples. We found that ALDH1 was expressed in 71 cases (18.2%) in the tumor cells and/or stroma. Of these cases, 38 (9.7%) showed ALDH1 expression in tumor cells and 38 (9.7%) showed ALDH1 expression in the stroma. ALDH1 expression was significantly associated with markers of a poor prognosis, such as young age, estrogen receptor negativity, progesterone receptor negativity, a high histological grade, and a high Ki-67 index. However, ALDH1 expression was not associated with p53, transforming growth factor-beta, Gli-1, YKL-40, or sonic hedgehog expression status. With regard to the expression site, the clinical characteristics did not differ between cases of cellular expression and those of stromal expression. However, ALDH1 expression in tumor cells was correlated with hormone receptor status, histological grade, molecular subtype, epidermal growth factor receptor expression status, and cytokeratin 5/6 expression status while stromal expression of ALDH1 was only correlated with hormone receptor status. Overall, these findings suggest that ALDH1 expression in tumor tissue is associated with a biologically aggressive phenotype.

AB - Aldehyde dehydrogenase 1 (ALDH1) has been regarded as a breast cancer stem cell marker. Several studies have reported that ALDH1 expression is associated with poor prognosis in breast cancer. We aimed, therefore, to determine the prognostic value of ALDH1 expression and its association with several biomarkers in breast cancer tissue using immunohistochemistry. Furthermore, we investigated the characteristics of and differences between cellular and stromal expression of ALDH1. We performed tissue microarray (TMA) analysis of 425 breast cancer tissue samples collected during surgery. Immunohistochemical staining was then performed to measure the expression of ALDH1 and other breast cancer biomarkers. Statistical analysis of the relationship between ALDH1 expression and clinicopathologic characteristics was performed for 390 TMA samples. We found that ALDH1 was expressed in 71 cases (18.2%) in the tumor cells and/or stroma. Of these cases, 38 (9.7%) showed ALDH1 expression in tumor cells and 38 (9.7%) showed ALDH1 expression in the stroma. ALDH1 expression was significantly associated with markers of a poor prognosis, such as young age, estrogen receptor negativity, progesterone receptor negativity, a high histological grade, and a high Ki-67 index. However, ALDH1 expression was not associated with p53, transforming growth factor-beta, Gli-1, YKL-40, or sonic hedgehog expression status. With regard to the expression site, the clinical characteristics did not differ between cases of cellular expression and those of stromal expression. However, ALDH1 expression in tumor cells was correlated with hormone receptor status, histological grade, molecular subtype, epidermal growth factor receptor expression status, and cytokeratin 5/6 expression status while stromal expression of ALDH1 was only correlated with hormone receptor status. Overall, these findings suggest that ALDH1 expression in tumor tissue is associated with a biologically aggressive phenotype.

KW - ALDH1

KW - Biologically aggressive

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84902332685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902332685&partnerID=8YFLogxK

U2 - 10.4149/neo_2014_045

DO - 10.4149/neo_2014_045

M3 - Article

C2 - 24824938

AN - SCOPUS:84902332685

VL - 61

SP - 352

EP - 362

JO - Neoplasma

JF - Neoplasma

SN - 0028-2685

IS - 3

ER -